ponvory™ 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg (treatment initiation pack) 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8
modern pharmaceutical company switzerland - 14's tablets [2 x 2mg tablets, 2 x 3mg tablets, 2 x 4mg tablets, 1 x 5mg tablet, 1 x 6mg tablet, 1 x 7mg tablet, 1 x 8mg tablet, 1 x 9mg tablet, 3 x 10mg tablets] - tablet - 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg / tablet - malignant disease,immunosuppresion-immune response
ponvory™ 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg (treatment initiation pack) 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8
modern pharmaceutical company switzerland - 14's tablets [2 x 2mg tablets, 2 x 3mg tablets, 2 x 4mg tablets, 1 x 5mg tablet, 1 x 6mg tablet, 1 x 7mg tablet, 1 x 8mg tablet, 1 x 9mg tablet, 3 x 10mg tablets] - tablet - 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg / tablet - malignant disease,immunosuppresion-immune response
ponvory™ 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg (treatment initiation pack) 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8
modern pharmaceutical company switzerland - 14's tablets [2 x 2mg tablets, 2 x 3mg tablets, 2 x 4mg tablets, 1 x 5mg tablet, 1 x 6mg tablet, 1 x 7mg tablet, 1 x 8mg tablet, 1 x 9mg tablet, 3 x 10mg tablets] - tablet - 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg / tablet - malignant disease,immunosuppresion-immune response
ponvory™ 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg (treatment initiation pack) 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg / tablet
modern pharmaceutical company switzerland - 14's tablets [2 x 2mg tablets, 2 x 3mg tablets, 2 x 4mg tablets, 1 x 5mg tablet, 1 x 6mg tablet, 1 x 7mg tablet, 1 x 8mg tablet, 1 x 9mg tablet, 3 x 10mg tablets] - tablet - 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg / tablet - malignant disease,immunosuppresion-immune response
tracleer
janssen-cilag (new zealand) ltd - bosentan 125mg; - film coated tablet - 125 mg - active: bosentan 125mg excipient: ethylcellulose glyceryl behenate hypromellose iron oxide red iron oxide yellow magnesium stearate maize starch povidone purified talc sodium starch glycolate starch titanium dioxide triacetin - tracleer® is indicated for the treatment of idiopathic pulmonary arterial hypertension, familial pulmonary arterial hypertension, pulmonary arterial hypertension associated with scleroderma or pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who class iii or iv symptoms.
tracleer
janssen-cilag (new zealand) ltd - bosentan 62.5mg (as monohydrate); - film coated tablet - 62.5 mg - active: bosentan 62.5mg (as monohydrate) excipient: ethylcellulose glyceryl behenate hypromellose iron oxide red iron oxide yellow magnesium stearate maize starch povidone purified talc sodium starch glycolate starch titanium dioxide triacetin - tracleer® is indicated for the treatment of idiopathic pulmonary arterial hypertension, familial pulmonary arterial hypertension, pulmonary arterial hypertension associated with scleroderma or pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who class iii or iv symptoms.
uptravi selexipag 800 microgram film-coated tablet blister pack
janssen-cilag pty ltd - selexipag, quantity: 800 microgram - tablet, film coated - excipient ingredients: hyprolose; iron oxide black; carnauba wax; titanium dioxide; maize starch; hypromellose; mannitol; propylene glycol; magnesium stearate; iron oxide yellow - uptravi is indicated for the treatment of:,- idiopathic pulmonary arterial hypertension;,- heritable pulmonary arterial hypertension;,- pulmonary arterial hypertension associated with connective tissue disease;,-pulmonary arterial hypertension associated with congenital heart disease with repaired shunts;,-pulmonary arterial hypertension associated with drugs and toxins;,in patients with who functional class ii, iii or iv symptoms
uptravi selexipag 1400 microgram film-coated tablet blister pack
janssen-cilag pty ltd - selexipag, quantity: 1400 microgram - tablet, film coated - excipient ingredients: mannitol; maize starch; hyprolose; hypromellose; propylene glycol; magnesium stearate; titanium dioxide; carnauba wax; iron oxide yellow - uptravi is indicated for the treatment of:,- idiopathic pulmonary arterial hypertension;,- heritable pulmonary arterial hypertension;,- pulmonary arterial hypertension associated with connective tissue disease;,-pulmonary arterial hypertension associated with congenital heart disease with repaired shunts;,-pulmonary arterial hypertension associated with drugs and toxins;,in patients with who functional class ii, iii or iv symptoms
uptravi selexipag 1600 microgram film-coated tablet blister pack
janssen-cilag pty ltd - selexipag, quantity: 1600 microgram - tablet, film coated - excipient ingredients: hypromellose; titanium dioxide; magnesium stearate; mannitol; iron oxide yellow; carnauba wax; hyprolose; maize starch; propylene glycol; iron oxide black; iron oxide red - uptravi is indicated for the treatment of:,- idiopathic pulmonary arterial hypertension;,- heritable pulmonary arterial hypertension;,- pulmonary arterial hypertension associated with connective tissue disease;,-pulmonary arterial hypertension associated with congenital heart disease with repaired shunts;,-pulmonary arterial hypertension associated with drugs and toxins;,in patients with who functional class ii, iii or iv symptoms
uptravi selexipag 1200 microgram film-coated tablet blister pack
janssen-cilag pty ltd - selexipag, quantity: 1200 microgram - tablet, film coated - excipient ingredients: titanium dioxide; hyprolose; maize starch; propylene glycol; iron oxide red; mannitol; hypromellose; magnesium stearate; carnauba wax; iron oxide black - uptravi is indicated for the treatment of:,- idiopathic pulmonary arterial hypertension;,- heritable pulmonary arterial hypertension;,- pulmonary arterial hypertension associated with connective tissue disease;,-pulmonary arterial hypertension associated with congenital heart disease with repaired shunts;,-pulmonary arterial hypertension associated with drugs and toxins;,in patients with who functional class ii, iii or iv symptoms